Sunshine Biopharma Inc. (OTCPink: SBFM) shares closed up 34.8 percent at $0.13655 in the last trading session. During the session, Sunshine Biopharma stock priced between $0.1047 and $0.165, while 10,312,405 were exchanged. After news of the successful conclusion of a study, SBFM stock rose.
What was the finding?
Sunshine Biopharma is a pharmaceutical company that specializes in developing anticancer and antiviral drugs. SBFM is developing Adva-27a as a treatment for several types of cancers. SBFM is also developing a compound named SBFM-PL4 that targets coronaviruses.
In a press release yesterday, Sunshine Biopharma said that the Maximum Tolerated Dose (MTD) study conducted in mice appeared to have been successful.
- Based on SBFM’s analysis of the MTD, the results are favorable and within the appropriate range for use in humans.
- Further, SBFM will conduct efficacy investigations on hACE2-transgenic mice using the test doses suggested by these results.
- SBFM’s COVID-19 treatment inhibits PLpro, a protease found only on SARS Coronaviruses, which plays a critical role in causing significant disease severity by impairing the host’s natural restorative immune system.
What does the SBFM CEO say?
CEO of Sunshine Biopharma, Steve Slilaty said that in general, Maximum Tolerable Dose (MTD) refers to the highest dose of a drug that does not result in unacceptable side effects or overt toxicity when taken over a specific period of time.
SBFM study specifications stipulated the use of a minimum number of animals, combined with endpoints such as clinical observation and liver function tests. In this critical toxicology study, Sunshine Biopharma (SBFM)’s compounds performed extremely well.